The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

One of the most important launches for Novartis in recent years is off with a bang. Following a broad FDA approval for the adjuvant treatment of HR-positive, HER2-negative early breast cancer in ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

INDIANAPOLIS (dpa-AFX) - Incyclix Bio, LLC announced Monday a clinical trial collaboration and supply agreement with Eli Lilly and Co. (LLY) for supply of its CDK4/6 inhibitor Verzenio ...